| Sep 16 |
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
|
| Sep 5 |
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
|
| Aug 19 |
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 13 |
Palisade Bio GAAP EPS of -$3.32
|
| Aug 13 |
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 8 |
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
|
| Jul 31 |
Palisade Bio Participates in Virtual Investor “What this Means” Segment
|
| Jul 29 |
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
|
| Jul 19 |
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
|
| Jul 11 |
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
|
